NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies

被引：1
|
作者：
Kyvsgaard, Emil R. [1 ,2 ,3 ,4 ]
Grauslund, Morten [5 ]
Sjo, Lene [5 ]
Melchior, Linea Cecilie [5 ]
Grantzau, Trine Lonbo [5 ]
Gjerdrum, Lise Mette Rahbek [6 ,7 ]
Trab, Trine [1 ,2 ]
Andersen, Laerke Sloth [1 ]
Gang, Anne Ortved [1 ,7 ]
Breinholt, Marie [7 ,8 ]
Moller, Michael Boe [9 ]
Christensen, Jacob Haaber [10 ]
Larsen, Thomas Stauffer [10 ]
Clausen, Michael Roost [11 ]
Riley, Caroline H. [1 ,3 ]
Niemann, Carsten U. [1 ,7 ]
Gronbaek, Kirsten [1 ,2 ,7 ]
Hutchings, Martin [1 ,3 ,7 ]
Husby, Simon [1 ,2 ,3 ]
机构：
[1] Rigshospitalet, Dept Hematol, Copenhagen, Denmark
[2] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark
[3] Rigshospitalet, Phase 1 Unit, Copenhagen, Denmark
[4] Aalborg Univ Hosp Thisted, Dept Internal Med, Thisted, Denmark
[5] Rigshospitalet, Dept Pathol, Copenhagen, Denmark
[6] Zealand Univ Hosp, Copenhagen Univ Hosp, Dept Pathol, Roskilde, Denmark
[7] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[8] Herlev Gentofte Hosp, Dept Pathol, Herlev, Denmark
[9] Odense Univ Hosp, Dept Pathol, Odense, Denmark
[10] Odense Univ Hosp, Dept Hematol, Odense, Denmark
[11] Vejle Sygehus, Dept Hematol, Vejle, Denmark
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 04期
关键词：
D O I：
10.1002/ajh.27601
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：712 / 716
页数：5
相关论文
共 50 条
  • [1] Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy
    Kyvsgaard, Emil R.
    Riley, Caroline
    Clausen, Michael Roost
    Harslof, Mads
    Heftdal, Line Dam
    Niemann, Carsten U.
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 356 - 360
  • [2] Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 Therapy
    Kyvsgaard, Emil Ramso
    Riley, Anna Caroline Hasselbalch
    Clausen, Michael Roost
    Harslof, Mads
    Heftdal, Line Dam
    Niemann, Carsten Utoft
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    BLOOD, 2023, 142
  • [3] CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)- a Multicenter Retrospective Study
    Dong, Ning
    Khadka, Sushmita
    Sandoval-Sus, Jose
    Rondon, Carlos Silva
    Perez, Ariel
    Al Sagheer, Tiba
    Iqbal, Madiha
    Alderuccio, Juan Pablo
    Arocho, Cristian Rodriguez
    Kareem, Syeda Saba
    Jain, Michael D.
    Chavez, Julio C.
    BLOOD, 2024, 144 : 3091 - 3092
  • [4] Combination of CD20xCD3 Bispecific Antibodies with Ibrutinib and Lenalidomide Shows Efficacy in Relapsed/ Refractory CNS Lymphoma
    Amorim, Sandy
    Carpentier, Benjamin
    Petit, Emmanuelle Bourgeois
    Hivert, Benedicte
    Thibaud, Vincent
    Willaume, Alexandre
    Pascal, Laurent
    BLOOD, 2024, 144 : 6453 - 6454
  • [5] Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Brouwer-Visser, Jurriaan
    Fiaschi, Nathalie
    Deering, Raquel P.
    Cygan, Kamil J.
    Scott, Darius
    Jeong, Se
    Boucher, Lauren
    Gupta, Namita T.
    Gupta, Suraj
    Adler, Christina
    Topp, Max S.
    Bannerji, Rajat
    Duell, Johannes
    Advani, Ranjana H.
    Flink, Dina M.
    Chaudhry, Aafia
    Thurston, Gavin
    Ambati, Srikanth R.
    Jankovic, Vladimir
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [6] Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting
    Sun, Hao
    Xing, Haizhou
    Han, Lijie
    Song, Yongping
    Jiang, Zhongxing
    Liu, Yanyan
    Yu, Jifeng
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 321 - 326
  • [7] In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20
    Bray, Joshua S.
    Thomas, Gethin R.
    Smith, Victoria M.
    Wright, Adam
    Jayne, Sandrine
    Dyer, Martin J. S.
    Walter, Harriet S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2025,
  • [8] CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma
    Ghobadi, Armin
    Bartlett, Nancy L.
    LANCET, 2021, 398 (10306): : 1109 - 1110
  • [9] Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models
    Schaadt, Eveline
    Heitmueller, Christina
    Peters, Solveig
    Ilieva, Kristina
    Blair, Derek
    Huth, Christiane
    Bartel, Dominik
    Zapf, Sandra
    Eberl, Markus
    Mangelberger-Eberl, Doris
    Giles, Frank
    Corvey, Carsten
    BLOOD, 2023, 142
  • [10] Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma
    Kyvsgaard, Emil Ramso
    Clausen, Michael Roost
    Riley, Anna Caroline Hasselbalch
    Niemann, Carsten Utoft
    Sjo, Lene
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    BLOOD, 2023, 142
12345